Searched for:
(1 - 4 of 4)
document
TNO Kwaliteit van Leven (author), Adourian, A. (author), Jennings, E. (author), Balasubramanian, R. (author), Hines, W.M. (author), Damian, D. (author), Plasterer, T.N. (author), Clish, C.B. (author), Stroobant, P. (author), McBurney, R. (author), Verheij, E.R. (author), Bobeldijk, I. (author), van der Greef, J. (author), Lindberg, J. (author), Kenne, K. (author), Andersson, U. (author), Hellmold, H. (author), Nilsson, K. (author), Salter, H. (author), Schuppe-Koistinen, I. (author)
High-throughput biomolecular profiling techniques such as transcriptomics, proteomics and metabolomics are increasingly being used in in vivo studies to recognize and characterize effects of xenobiotics on organs and systems. Of particular interest are biomarkers of treatment-related effects which are detectible in easily accessible biological...
article 2008
document
van der Greef, J. (author), Martin, S. (author), Juhasz, P. (author), Adourian, A. (author), Plasterer, T. (author), Verheij, E.R. (author), McBurney, R.N. (author), TNO Kwaliteit van Leven (author)
Systems biology has developed in recent years from a technology-driven enterprise to a new strategic tool in Life Sciences, particularly for innovative drug discovery and drug development. Combining the ultimate in systems phenotyping with in-depth investigations of biomolecular mechanisms will enable a revolution in our understanding of disease...
article 2007
document
van der Greef, J. (author), Hankemeier, T. (author), McBurney, R.N. (author), TNO Kwaliteit van Leven (author)
Personalized medicine - defined as customized medical care for each patient's unique condition - in the broader context of personalized health, will make significant strides forward when a systems approach is implemented to achieve the ultimate in disease phenotyping and to create novel therapeutics that address system-wide molecular...
article 2006
document
van der Greef, J. (author), McBurney, R.N. (author), TNO Kwaliteit van Leven (author)
The pharmaceutical industry is currently beleaguered by close scrutiny from the financial community, regulators and the general public. Productivity, in terms of new drug approvals, has generally been falling for almost a decade and the safety of a number of highly successful drugs has recently been brought into question. Here, we discuss...
article 2005
Searched for:
(1 - 4 of 4)